COVID-19

TIME Mag - "Why Masks Still Matter". 1) COVID is still out there; 2) Influenza on the rise. Authors write "With limited yet mixed data, we would be wise to ...err on the side of masking in high risk, indoor crowded public settings..." https://t.co/l8jiTwAdZz https://t.co/0QUKJDOhjs

Links:

Dr. John Cush @RheumNow( View Tweet )
Nov 28, 2022
Does Evusheld shield people living with rheumatic diseases? Dr. Yuz Yusof ( @Yuz6Yusof) discusses three key abstracts from #ACR22 on Evusheld findings.https://t.co/wYl6Wpd5Fs https://t.co/7T7u4czNOX

Links:

Dr. John Cush @RheumNow( View Tweet )
Nov 27, 2022
COVID Highlights Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at #ACR22 https://t.co/DEUykGt8pT https://t.co/sz8GRRGrPH

Links:

Dr. John Cush @RheumNow( View Tweet )
Nov 23, 2022
Impact of COVID 19 on Pregnancies in Women with RMD Dr. Cassy Sims ( @DrCassySims) discusses abstract 0950 at #ACR22. https://t.co/qbFRV5P3eP https://t.co/cmS4n15L5e

Links:

Dr. John Cush @RheumNow( View Tweet )
Nov 23, 2022
Vaccination +/- prior Covid-19, and with either mRNA or vectored DNA vaccines were not associated with AIRD flares. Negative association 21-days after 1st Covid-19 vaccination and no association after 2nd or 3rd doses. Nakafero G Abs#2194 https://t.co/vA8cMNQGkr #ACR22 @RheumNow https://t.co/SZnXejnmYt

Links:

Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 14, 2022
Problem w antibodies to prevent #COVID19 infection in rheumatic Pts is that they are not as good in variants that are more prominent ex Omicron strains. But should we use in high risk Pts ex long rituximab users? I do in this group. @RheumNow #ACR22 https://t.co/A8soYbg9ZD

Links:

Janet Pope @Janetbirdope( View Tweet )

Nov 14, 2022
L08 #ACR22 TIX/CIL (Evusheld) in Rheum Pts 157 pts, f/u 154 days 24 breakthrough COVID ifns (15%) 2 pts required hospitalization, rest had mild-mod symptoms No SAEs (CVD) @RheumNow

Eric Dein @ericdeinmd( View Tweet )

Nov 14, 2022
In a prospective cohort where MTX was withheld for 1 week post COVID vaccine, antibodies higher than other DMARDs which were continued (mostly RTX/MMF). Good to see more direct data rather than having to extrapolate from flu. @RheumNow ABST0913 #ACR22https://t.co/YphKywNJfA

Links:

Julian Segan @JulianSegan( View Tweet )

Nov 14, 2022
Even young SLE patients are still at high risk of severe COVID: - in general pop, age is key factor - in SLE, risk is high across age groups (maybe due to both meds & disease) - vaccination makes a big diff but SLE pts still at high risk ABST1591 @CCalabreseDO #ACR22 @RheumNow https://t.co/ra1F79ITn3
David Liew @drdavidliew( View Tweet )
Nov 14, 2022
syringe,needle,vaccine

Vaccine Efficacy in Patients with Seronegative Spondyloarthritis

Catherine Sims, MD
Nov 14, 2022

Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.

Read Article
#ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group @RheumNow https://t.co/iucDK1GpU4
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 14, 2022
The pandemic has brought many challenges to our community. One of them is the lingering effects of COVID-19. #PASC #COVID #ACR22 #RheumTwitter https://t.co/AlwUHX2cao

Links:

Akhil Sood MD @AkhilSoodMD( View Tweet )

Nov 14, 2022
All monster stories end with an unexpected award: A new order @cuttingforstone at #ACR22 tells the monster story of #covid “How will history review our story?” The science will get an A+, but we failed to learn the lessons of history All was predictable through history @RheumNow

Eric Dein @ericdeinmd( View Tweet )

Nov 13, 2022
Everyday heroes during #COVID19 Keynote @ACRheum Health care workers who were minorities disproportionately died in the early days of the pandemic. Can’t be all SES as risk but maybe ‘status’ as first line workers. Remember them #ACRBest #ACR22 @RheumNow @AbrahamVerghese 🙏🏻 https://t.co/AjkV5wDVEu
Janet Pope @Janetbirdope( View Tweet )
Nov 13, 2022
Please read my short review on early experience/data pertaining to the use of #Evusheld in patients with rheumatic and musculoskeletal diseases presented at #ACR22 @RheumNow https://t.co/JA7WsWqMmz https://t.co/MRA0mQFIu8

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 13, 2022
Does MTX dose matter for COVID mRNA vaccine immunogenicity in RA pts? Single-center (n=126) with one MTX dose WH post-each vaccine Similar humoral response Big error bars suggest other factors more important ABST0913 #ACR22 @RheumNow (not pretty graphs but data interesting!) https://t.co/FFfTWiNjUY
David Liew @drdavidliew( View Tweet )
Nov 13, 2022
covid coronavirus virus

Does Evusheld shield people living with rheumatic diseases?

Md Yuzaiful Md Yusof, MRCP(UK), PhD
Nov 13, 2022

While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with

Read Article
💉COVID-19 vaccination in pregnant pts with rheumatic disease💉 🤰⬇️pre term births in vaccinated 🤰PPROM ⬆️ unvaccinated ✅More support 4 importance of covid vacc in our 🤰 Stellar work from covid GRA- Fantastic presentation by @Sineadm15 #ACR22 @RheumNow @RichardPAConway https://t.co/LLaLJSqS6W
Patricia Harkins @DrTrishHarkins( View Tweet )
Nov 13, 2022
#ACR22 Abstr#0799 Is Evusheld effective in patients on B-cell depleting therapies? Early data (Jan-May 22) from @CCalabreseDO @LCalabreseDO are encouraging: 13/417 (3%) breakthrough infection in fully vac pts, 1 hospitalised. More data needed for Omicron subvariants @RheumNow https://t.co/g4Y1IMO67X
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 13, 2022
Ab0685 #ACR22 APLS and prior COVID infection TKR patients at HSS: 1/5 of patients had positive aPL Ab, mostly low level aCL IgM Not associated with COVID infection or SARS-CoV-2 Ab @RheumNow https://t.co/HJpnUOrrxc
Eric Dein @ericdeinmd( View Tweet )
Nov 13, 2022
Please do catch up on my interview with Dr Amit Saxena, New York on their work. #ACR22 Abstr#2081 Breakthrough COVID infection in SLE during Omicron era https://t.co/4dINWSobxj via @YouTube @RheumNow https://t.co/hIHWGRcu5h

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 13, 2022
Getting to know the COVID-19 drugs: ◦ Pre-exposure prophylaxis: Tixagevimab and cilgavimab (Evusheld) ◦ Post-exposure treatments: Paxlovid (po), Molnupiravir (po), Sotrovimab (IV), Remdesivir (IV) Rachael Perritt, COVID-19, #ACR22 @RheumNow https://t.co/bCwxJ9YfIU
Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 13, 2022
Year in Review #ACR22 Pre-expos PPx for COVID! Tix-Cil (Evusheld): risk reduction 77% Cardiac AES 0.6% vs placebo 0.2% Only 3.3% were on immunosuppression But Israeli study with immunosuppressed: 92% half as likely to be hospitalized or die 1/2 less infections @RheumNow

Eric Dein @ericdeinmd( View Tweet )

Nov 12, 2022
We share our vision of what rheumatologists should be considering thinking and doing regarding COVID-19 in our immunocompromise patients. Would love your reactions @CCalabreseDO @BetsyKirch @DrPujaMehta1 @alhkim @drdavidliew @philipcrobinson #ACR22 https://t.co/OpmoEOXWmL

Links:

Leonard Calabrese @LCalabreseDO( View Tweet )

Nov 12, 2022
#ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID and protect our immunosuppressed patients @RheumNow https://t.co/lZSDRj3bkm
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 12, 2022

Recent Blogs

A Guide to Self Care of (Mild) COVID19

Kathryn H. Dao, M.D.
Jan 25, 2022
morbidity,covid,heart,lung,brain
There is guidance published on how to manage moderate to severe cases, but very few blueprints detail what to do with “mild” infection.  The first day, I developed congestion and cough, with a sore throat.  As the day progressed, I started to have chills, low grade fevers, and myalgias.  The postnasal drainage was overwhelming, and when I tried to swallow, it felt like swallowing broken glass.  Isolating in my room, I was left to deal with my symptoms.Read Post

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2022 All Rights Reserved.

×